MDS
Myelodysplastic syndromes (MDS) are diseases of the blood cells and bone marrow. MDS are a collection of myeloid malignancies characterized by one or more peripheral blood cytopenias. Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.
The proof-of-concept study showed that noninvasive hemoglobin measurement is “feasible,” but there were several ...
One aim is to evaluate the efficacy of oral decitabine/cedazuridine and magrolimab in intermediate to HR MDS.
Joseph Khoury, MD; Sanam Loghavi, MD; and Chadi Nabhan, MD, MBA, FACP, discuss the MDS classification systems.
Dr. Garcia-Manero discusses key data from the phase III COMMANDS trial.
Dr. Komrokji speaks about what might follow the recent FDA approval of luspatercept for certain patients with MDS.
Researchers sought to differentiate the mechanism of action of luspatercept from epoetin alfa.
Dr. Hasserjian discusses a presentation about the classification system that he gave at the SOHO Annual Meeting.
A research team sought in their study to determine if the IPSS-M could also apply to CMML.
"There's been a lot of focus on classifications and mutations: they're coming with a lot of force," Dr. Scheinberg said.
Dr. Platzbecker joins Chadi Nabhan, MD, MBA, FACP, to discuss MDS at the Eleventh Annual Meeting of SOHO.
Guillermo Garcia-Manero, MD, joins Chadi Nabhan, MD, MBA, FACP, to discuss the COMMANDS trial at the SOHO Annual Meeting.
Allogeneic HSCT can yield favorable outcomes in treating patients with therapy-related MDS.
A presentation by Dr. Rami Komrokji at the Eleventh SOHO Annual Meeting gave additional insights into the COMMANDS trial.
Luspatercept is highly effective in treating ESA-naïve patients with LR-MDS.
Response rates were high, and OS was improved in patients receiving venetoclax, although not statistically significant.
The expanded indication to the frontline setting is based on interim results from the pivotal phase III COMMANDS trial.
Guillermo Garcia-Manero, MD, the 2023 SOHO President-Elect, shares his hopes and goals for the coming years.
The study's authors found evidence showing that "heme might serve as a rheostat directing cells to live or die."
Gilead Sciences, Inc, the manufacturer of the drug, recommends discontinuing magrolimab treatment in patients with MDS.
The single-center phase I/II study evaluated the triplet combination after hypomethylating agent failure.
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
The FDA has removed the partial clinical hold on the TakeAim Leukemia phase I/II study of emavusertib.
The study compared luspatercept with epoetin alfa in patients with lower-risk MDS who were naive to ESA treatment.
An NDA for the telomerase inhibitor imetelstat has been submitted to the FDA.
Dr. Winer discusses emavusertib, an orally bioavailable, reversible inhibitor of IRAK4.
Dr. Venugopal, who was not involved in the study, discusses the results and implications of the phase III trial.
The median OS was 13.3 months in patients receiving CPX-351, while it was 11.4 months in those receiving FLAG-Ida.
In the 84 patients with MDS who were identified as vulnerable, 88% had difficulty with prolonged physical activity.
The investigators replicated the statistical plan of the MEDALIST trial to evaluate luspatercept outside of a clinical trial.
KER-050 is a modified activin receptor type IIA ligand trap designed to inhibit select TGF-β superfamily ligands.
The study evaluated imetelstat versus placebo in patients with lower-risk MDS who were highly transfusion dependent.
Dr. Stéphane De Botton discusses his EHA abstract on tamibarotene-based therapy in MDS/AML.
Dr. Garcia-Manero presented results from the phase III COMMANDS trial during the 2023 ASCO Meeting.
Most patients (82%) had a low transfusion burden at baseline.
A subset of TP53-mutated myeloid neoplasms, such as MDS, are preceded by TP53-mutated CCUS.
Nearly one-third (29%) of patients were upstaged from their IPSS-R score by the IPSS-M.
Dr. Garcia-Manero presented information about a phase Ib study of IRAK1/4 inhibition at the 2023 ASCO Annual Meeting.
In this video, Dr. Garcia-Manero discusses the study's primary endpoint, its implications for patients, and more.
Dr. Zeidan speaks about the rationale behind the trial, the implications of its results, and the next steps.
The field of hematologic oncology is now contending with reconciling the proposed rival WHO and ICC systems.
The Type II Variation Application was accepted by the European Medicines Agency (EMA) as well.
Dr. Zeidan discusses a patient who shaped his career path, the pressing questions in MDS and AML, and more.
Certain cellular pathways were upregulated in patients with myelodysplastic syndromes (MDS) who responded to immunotherapy.
Researchers retrospectively screened patients with VEXAS for clonal hematopoiesis in their peripheral blood.
The study assessed “patterns of consideration” for HSCT and identified factors associated with transplant referral rates.
The study showed starting statin therapy at MDS diagnosis was associated with a 38% improvement in OS.
Novel targets are under investigation in several types of hematologic malignancies.
The ICC and WHO both “proposed significant changes” to the diagnostic criteria for MDS in 2022.
In patients with TP53 mutations, 40% achieved a complete response, with a median OS of 16.3 months.
The three-year OS rate was 91.3% for patients who were MRD negative, while it was 66.4% for those who were MRD positive.
Advertisement
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Advertisement
